Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 543-548

  Duncan, R Scott ^a   Xin, Hua ^a   Goad, Daryl L ^a   Chapman, Kent D ^b   Koulen, Peter ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

Calcium signaling; Eye; Glaucoma; Glutamate; Immunocytochemistry; Neuroprotection; Vision

Indexed keywords

ENDOCANNABINOID; GLUTAMIC ACID; N ACYLETHANOLAMINE; N LINOLEOYLETHANOLAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; EX VIVO STUDY; EXCITOTOXICITY; GLAUCOMA; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NICK END LABELING; NONHUMAN; RETINA GANGLION CELL;

EID: 79957521210     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S18309     Document Type: Article

References (50)

1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004; 363:1711-1720.
2. Yuan L, Neufeld AH. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia. 2000;32:42-50.
3. Moreno MC, Campanelli J, Sande P, Sánez DA, Keller Sarmiento MI, Rosenstein RE. Retinal oxidative stress induced by high intraocular pressure. Free Radic Biol Med. 2004;37:803-812.
4. Seki M, Lipton SA. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. Prog Brain Res. 2008;173:495-510.
5. Hare WA, Wheeler L. Experimental glutamatergic excitotoxicity in rabbit retinal ganglion cells: block by memantine. Invest Ophthalmol Vis Sci. 2009;50:2940-2948.
6. Son JL, Soto I, Oglesby E, et al. Glaucomatous optic nerve injury involves early astrocyte reactivity and late oligodendrocyte loss. Glia. 2010;58:780-789.
7. Hahn JS, Aizenman E, Lipton SA. Central mammalian neurons normally resistant to glutamate toxicity are made sensitive by elevated extracel- lular Ca2+: toxicity is blocked by the N-methyl-D-aspartate antagonist MK-801. Proc Natl Acad Sci U S A. 1988;85: 6556-6560.
8. Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 1996;37: 1618-1624.
9. Otori Y, Wei JY, Barnstable CJ. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 1998;39:972-981.
10. WoldeMussie E, Yoles E, Schwartz M, Ruiz G, Wheeler LA. Neuroprotective effect of memantine in different retinal injury models in rats. J Glaucoma. 2002;11:474-480.
11. Manabe S, Gu Z, Lipton SA. Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2005;46:4747-4753.
12. Chidlow G, Wood JP, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs. 2007;67:725-759.
13. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 2009;87:450-454.
14. Sun Q, Ooi VE, Chan SO. N-methyl-D-aspartate-induced excitotoxicity in adult rat retina is antagonized by single systemic injection of MK-801. Exp Brain Res. 2001;138:37-45.
15. Xin H, Yannazzo JA, Duncan RS, Gregg EV, Singh M, Koulen P. A novel organotypic culture model of the postnatal mouse retina allows the study of glutamate-mediated excitotoxicity. J Neurosci Methods. 2007;159:35-42.
16. Epps DE, Schmid PC, Natarajan V, Schmid HH. N-Acylethanolamine accumulation in infarcted myocardium. Biochem Biophys Res Commun. 1979;90:628-633.
17. Epps DE, Natarajan V, Schmid PC, Schmid HO. Accumulation of N-acylethanolamine glycerophospholipids in infarcted myocardium. Biochim Biophys Acta. 1980;618:420-430.
18. Natarajan V, Schmid PC, Schmid HH. N-acylethanolamine phospholipid metabolism in normal and ischemic rat brain. Biochim Biophys Acta. 1986;878:32-41.
19. Hansen HS, Lauritzen L, Strand AM, Moesgaard B, Frandsen A. Glutamate stimulates the formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cortical neurons in culture. Biochim Biophys Acta. 1995;1258:303-308.
20. Moesgaard B, Jaroszewski JW, Hansen HS. Accumulation of N- acyl-ethanolamine phospholipids in rat brains during post-decapitative ischemia: a 31p NMR study. J Lipid Res. 1999;40:515-521.
21. Schäbitz WR, Giuffrida A, Berger C, et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke. 2002;33:2112-2114.
22. Duncan RS, Chapman KD, Koulen P. The neuroprotective properties of palmitoylethanolamine against oxidative stress in a neuronal cell line. Mol Neurodegener. 2009;4:50.
23. Garg P, Duncan RS, Kaja S, Koulen P. Intracellular mechanisms of N-acylethanolamine-mediated neuroprotection in a rat model of stroke. Neuroscience. 2010;166:252-262.
24. Chen J, Matias I, Dinh T, et al. Finding of endocannabinoids in human eye tissues: implications for glaucoma. Biochem Biophys Res Commun. 2005;330:1062-1067.
25. Straiker AJ, Maguire G, Mackie K, Lindsey J. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci. 1999;40:2442-2448.
26. Yazulla S, Studholme KM, McIntosh HH, Deutsch DG. Immunocy- tochemical localization of cannabinoid CB1 receptor and fatty acid amide hydrolase in rat retina. J Comp Neurol. 1999;415:80-90.
27. Lu Q, Straiker A, Lu Q, Maguire G. Expression of CB2 cannabinoid receptor mRNA in adult rat retina. Vis Neurosci. 2000;17:91-95.
28. Glaser ST, Deutsch DG, Studholme KM, Zimov S, Yazulla S. Endocannabinoids in the intact retina: 3 H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamide. Vis Neurosci. 2005;22:693-705.
29. Zimov S, Yazulla S. Vanilloid receptor 1 (TRPV1/VR1) co-localizes with fatty acid amide hydrolase (FAAH) in retinal amacrine cells. Vis Neurosci. 2007;24:581-591.
30. Hu SS, Arnold A, Hutchens JM, Radicke J, et al. Architecture of cannabinoid signaling in mouse retina. J Comp Neurol. 2010;518: 3848-3866.
31. El-Remessy AB, Khalil IE, Matragoon S, et al. Neuroprotective effect of (-) Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D- aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol. 2003;163:1997-2008.
32. Mafe OA, Gregg EV, Medina-Ortiz WE, Koulen P. Localization of inositol 1,4,5-trisphosphate receptors in mouse retinal ganglion cells. J Neurosci Res. 2006;84:1750-1758.
33. Ullian EM, Barkis WB, Chen S, Diamond JS, Barres BA. Invulnerability of retinal ganglion cells to NMDA excitotoxicity. Mol Cell Neurosci. 2004;26:544-557.
34. Wamsley S, Gabelt BT, Dahl DB, et al. Vitreous glutamate concen- tration and axon loss in monkeys with experimental glaucoma. Arch Ophthalmol. 2005;123:64-70.
35. Matias I, Wang JW, Moriello AS, Nieves A, Woodward DF, Di Marzo V. Changes in endocannabinoid and palmitoylethanolamide levels in eye tis-sues of patients with diabetic retinopathy and age-related macular degen-eration. Prostaglandins Leukot Essent Fatty Acids. 2006;75:413-418.
36. Nucci C, Gasperi V, Tartaglione R, et al. Involvement of the endocannab- inoid system in retinal damage after high intraocular pressure-induced ischemia in rats. Invest Ophthalmol Vis Sci. 2007;48:2997-3004.
37. Jonsson KO, Vandevoorde S, Lambert DM, Tiger G, Fowler CJ. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol. 2001;133:1263-1275.
38. Movahed P, Jönsson BA, Birnir B, et al. Endogenous unsaturated C18 N-acylethanolamines are vanilloid receptor (TRPV1) agonists. J Biol Chem. 2005;280:38496-38504.
39. Howlett AC, Qualy JM, Khachatrian LL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol. 1986;29:307-313.
40. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605-613.
41. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuro- blastoma-glioma cells. Proc Natl Acad Sci U S A. 1992;89:3825-3829.
42. Bouaboula M, Poinot-Chazel C, Bourrié B, et al. Activation of mitogen- activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J. 1995;312:637-641.
43. Henry DJ, Chavkin C. Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in Xenopus oocytes. Neurosci Lett. 1995;186:91-94.
44. Derkinderen P, Toutant M, Burgaya F, et al. Regulation of a neuronal form of focal adhesion kinase by anandamide. Science. 1996;273: 1719-1722.
45. Derkinderen P, Ledent C, Parmentier M, Girault JA. Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J Neurochem. 2001;77:957-960.
46. Lambert DM, Di Marzo V. The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem. 1999;6:757-773.
47. Maccarrone M, Lorenzon T, Bari M, Melino G, Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem. 2000;275:31938-31945.
48. Shirakawa H, Yamaoka T, Sanpei K, Sasaoka H, Nakagawa T, Kaneko S. TRPV1 stimulation triggers apoptotic cell death of rat cortical neurons. Biochem Biophys Res Commun. 2008;377:1211-1215.
49. Ashton JC, Appleton I, Darlington CL, Smith PF. Immunohistochemical localization of cerebrovascular cannabinoid CB1 receptor protein. J Cardiovasc Pharmacol. 2004;44:517-519.
50. Wagner JA, Járai Z, Bátkai S, Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol. 2001;423:203-210.